Editorial: Immunomodulatory factors, conversion, and postoperative adjuvant therapy for hepatobiliary tumors based on immunotherapy.
作者信息
Zhang Er-Lei
机构信息
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出版信息
Front Immunol. 2023 May 23;14:1218845. doi: 10.3389/fimmu.2023.1218845. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Immunomodulatory factors, conversion, and postoperative adjuvant therapy for hepatobiliary tumors based on immunotherapy.社论：基于免疫疗法的肝胆肿瘤免疫调节因子、转化及术后辅助治疗
Front Immunol. 2023 May 23;14:1218845. doi: 10.3389/fimmu.2023.1218845. eCollection 2023.
2
A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.肝细胞癌根治性切除术后辅助性细胞因子诱导的杀伤细胞免疫治疗的随机对照试验。
Dig Liver Dis. 2009 Jan;41(1):36-41. doi: 10.1016/j.dld.2008.04.007. Epub 2008 Sep 25.
3
Post-operative adjuvant immunotherapy with cytokine-induced killer and dendritic cells for hepatocellular carcinoma: A systematic review and meta-analysis.细胞因子诱导的杀伤细胞和树突状细胞用于肝细胞癌术后辅助免疫治疗：一项系统评价和荟萃分析。
Asian J Surg. 2023 Jun;46(6):2433-2436. doi: 10.1016/j.asjsur.2022.12.049. Epub 2023 Jan 2.
4
5
Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.经肝动脉灌注化疗联合抗 PD-1/PD-L1 免疫治疗及分子靶向药物治疗晚期肝细胞癌的真实世界研究。
Front Immunol. 2023 Apr 26;14:1127349. doi: 10.3389/fimmu.2023.1127349. eCollection 2023.
6
Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma.可切除肝细胞癌的新辅助治疗和辅助治疗
Cochrane Database Syst Rev. 2000(2):CD001199. doi: 10.1002/14651858.CD001199.
7
The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.细胞因子诱导的杀伤细胞输注作为辅助治疗用于肝癌术后患者的疗效。
Ann Surg Oncol. 2013 Dec;20(13):4305-11. doi: 10.1245/s10434-013-3144-x. Epub 2013 Jul 27.
8
Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data.细胞因子诱导的杀伤细胞免疫疗法辅助治疗肝细胞癌：真实世界数据的倾向性评分匹配分析。
BMC Cancer. 2019 May 31;19(1):523. doi: 10.1186/s12885-019-5740-z.
9
[Pre- and/or postoperative adjuvant therapy for hepatocellular carcinoma].[肝细胞癌的术前和/或术后辅助治疗]
Nihon Geka Gakkai Zasshi. 1998 Apr;99(4):229-33.
10
Immunotherapy and targeted therapy converted radical surgery in an advanced hepatocellular carcinoma with tumor emboi of portal vein and hepatic vein.免疫疗法和靶向疗法使一名伴有门静脉和肝静脉瘤栓的晚期肝细胞癌患者转变为可进行根治性手术。
Asian J Surg. 2021 Oct;44(10):1302-1304. doi: 10.1016/j.asjsur.2021.06.044. Epub 2021 Jul 24.
引用本文的文献
1
Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report.优化辅助性免疫检查点抑制剂治疗持续时间对转化治疗后肝细胞癌术后治疗的重要性：一例病例报告
J Surg Case Rep. 2023 Nov 11;2023(11):rjad610. doi: 10.1093/jscr/rjad610. eCollection 2023 Nov.
本文引用的文献
1
A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights.《2022年中国肝细胞癌管理临床指南综述：更新与见解》
Hepatobiliary Surg Nutr. 2023 Apr 10;12(2):216-228. doi: 10.21037/hbsn-22-469. Epub 2023 Mar 2.
2
Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion.伴有微血管侵犯的肝细胞癌的术后辅助治疗
World J Gastrointest Surg. 2023 Jan 27;15(1):19-31. doi: 10.4240/wjgs.v15.i1.19.
3
Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?肝细胞癌中的免疫疗法：它将如何重塑治疗顺序？
Ther Adv Med Oncol. 2023 Jan 10;15:17588359221148029. doi: 10.1177/17588359221148029. eCollection 2023.
4
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.多中心 III 期随机对照研究：伴有微血管侵犯的肝细胞癌术后肝动脉灌注化疗 FOLFOX 方案的疗效观察。
J Clin Oncol. 2023 Apr 1;41(10):1898-1908. doi: 10.1200/JCO.22.01142. Epub 2022 Dec 16.
5
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.晚期肝细胞癌中阿替利珠单抗联合贝伐珠单抗治疗的临床反应和耐药的分子相关性。
Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23.
6
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
7
Revisiting Surgical Strategies for Hepatocellular Carcinoma With Microvascular Invasion.重新审视伴有微血管侵犯的肝细胞癌的手术策略
Front Oncol. 2021 May 27;11:691354. doi: 10.3389/fonc.2021.691354. eCollection 2021.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.IMbrave 050：阿替利珠单抗联合贝伐珠单抗用于根治性切除或消融治疗后高危肝细胞癌的 III 期临床试验。
Future Oncol. 2020 May;16(15):975-989. doi: 10.2217/fon-2020-0162. Epub 2020 Apr 30.
10
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.肝细胞癌合并门静脉癌栓患者的管理：东西比较。
Lancet Gastroenterol Hepatol. 2019 Sep;4(9):721-730. doi: 10.1016/S2468-1253(19)30178-5.
Zotero 插件